Governance at a Glance

Chair
Member
Board Members Audit Compensation Nominating and Corporate Governance Regulatory Compliance

Stephen J. Sullivan

Jack Stover

Edward Chan

Robert Gorman

Joseph Keegan, Ph.D.

Eric Lev

Ron Rocca

Committee Charters

Stephen J. Sullivan

Stephen J. Sullivan was appointed Chairman of the Board effective June 21, 2016. Mr. Sullivan served as Interim Chairman of the Board from January 1, 2016 to June 20, 2016. Mr. Sullivan joined us as a director in September 2004 and has served as Chairman of various committees of the Board. In early 2010, Mr. Sullivan founded CRO Advisors LLC, a specialty consulting firm he continues to head. Previously, Mr. Sullivan was the president and chief executive officer and a member of the board of directors of Harlan Laboratories, Inc. (“Harlan”), a privately held global provider of preclinical research tools and services, from February 2006 through January 2010, when he retired from that position. Prior to joining Harlan in 2006, Mr. Sullivan was a senior vice president of Covance, Inc. (“Covance”) and the president of Covance Central Laboratories, Inc., a major division of Covance. Prior to joining Covance, Mr. Sullivan was chairman and chief executive officer of Xenometrix, Inc., a biotechnology company with proprietary gene expression technology. He assisted with the merger of Xenometrix with Discovery Partners International. Prior to Xenometrix, Mr. Sullivan was vice president and general manager of a global diagnostic sector of Abbott Laboratories. Since June 2013 and May 2013, Mr. Sullivan has been the chairman of the board of Bioreclamation IVT, LLC, a privately owned bio-materials company, and a member of the board of directors of PHT Corporation, a privately owned leader in electronic patient recorded outcomes in clinical trials, respectively. Since April 2011, Mr. Sullivan has been chairman of the board of MI Bioresearch, Inc. (formerly known as Molecular Imaging, Inc.), a venture-backed drug discovery services company. Since May 2015, Mr. Sullivan has been chairman of the board of Microbiology Research Associates, a microbiology services company. In January 2016, Mr. Sullivan became chairman of the board of H2O Clinical, a specialty contract research organization, and in November 2015, Mr. Sullivan joined the board of Accel Clinical Research, a Phase 1 contract research organization. Mr. Sullivan graduated from the University of Dayton, was a commissioned officer in the Marine Corps, and completed his M.B.A. in Marketing and Finance at Rutgers University. Mr. Sullivan has held senior leadership positions in companies in the life sciences and healthcare services industries.

Jack Stover

Jack Stover

Mr. Stover has been President and CEO of Interpace Biosciences since 2016 and a member of its Board of Directors for nearly 20 years under its former parent PDI, Inc. Previously he was Chief Executive Officer of Zebec Therapeutics LLC ("Zebec") since April 2014. Zebec is the successor to Quadrant Pharmaceuticals LLC, which Mr. Stover co-founded and was President and Director of from September 2013. From 2009 to February 2012, Mr. Stover served as the executive chairman of Targeted Nano Therapeutics LLC, a privately held biotechnology company focused on targeted delivery of peptides and proteins. Mr. Stover was also chairman of the audit committee and a member of the board of directors of Arbios Systems Inc. from 2005 to 2008 and a member of the board of directors of Influmedix, Inc. from 2010 to 2011.

From 2004 to 2008, he served as chief executive officer, president and director of Antares Pharma, Inc., a publicly held specialty pharmaceutical company listed on the American Stock Exchange. Prior to that, Mr. Stover was executive vice president and chief financial officer of Sicor, Inc., a publicly held company which manufactured and marketed injectable pharmaceutical products, and which was acquired by Teva Pharmaceutical Industries. Prior to that, Mr. Stover was executive vice president and director of a proprietary women's pharmaceutical company, Gynetics, Inc. ("Gynetics"), and before Gynetics, he was senior vice president and director of B. Braun Medical, Inc., a private global medical device and pharmaceutical company. For more than five years prior to that, Mr. Stover was a partner with PricewaterhouseCoopers (then Coopers and Lybrand), working in the lifesciences industry division. Mr. Stover received his B.A. in Accounting from Lehigh University and is a Certified Public Accountant.

Edward Chan

Edward Chan was appointed to the Board effective January 15, 2020.  Mr. Chan has over 12 years of experience in healthcare investing.  Since 2016, Mr. Chan has been a principal at 1315 Capital, a Philadelphia-based firm that provides expansion and growth capital to healthcare companies.  Prior to 1315 Capital, Mr. Chan was a vice president at NaviMed Capital, a lower middle-market healthcare investment firm and an associate at Siemens Venture Capital, the investment arm of Siemens.  Edward started his career developing and commercializing a molecular diagnostic product at a venture backed company.  Mr. Chan has been involved in several diagnostics and biopharma services investments including China Diagnostics Medical Corporation (acquired by Actis Capital), BioImagene (acquired by Roche), RadPharm (acquired by JLL Partners), Cylex (acquired by Viracor-IBT), Sequenom (acquired by LabCorp) and Genoptix (acquired by NeoGenomics). He currently serves on the board of Centurion Service Group.  Mr. Chan received a BSc in Biomedical Engineering from Johns Hopkins University and an MBA from the Wharton School at the University of Pennsylvania.

Robert Gorman

Robert Gorman was appointed to the Board in January, 2020.   Mr. Gorman experiences include over 30 years in healthcare leadership positions. The majority of his career has been in laboratory services industry with both public and private Companies.  After leaving public accounting he served as Operations Controller for Home Medical Systems, a Company focused on the roll-up of the Durable Medical Equipment business in the U.S.  The company was sold to Beverly Enterprises.  He joined Central Diagnostic Laboratory, the largest independent Laboratory at the time, as East Coast Controller, which was acquired by Corning Clinical Laboratory (now known as Quest Diagnostics).  He spent over 20 years at Quest Diagnostics.  While at Quest he held various leadership roles including responsibility for Quest’s New York and New England Laboratories, the East Region and ultimately became the Vice President of U.S. Operations.  After retiring from Quest, he along with WaterStreet Healthcare partners acquired Converge Diagnostics Laboratory, where he served as Chief Executive Officer.  He transformed the Company into a full service regional Lab Services Company servicing the New England market.  After approximately 4 ½ years the Company was acquired by Quest Diagnostics. Several years later, he joined Eurofins, an International Laboratory Company, as Senior Vice President of U. S. Clinical Diagnostics, with responsibility for Eurofins’ Clinical Diagnostic businesses in the U.S.

He has served on several for profit and not for profit boards over the years. 

Joseph Keegan, Ph.D.

Joseph Keegan, Ph.D. was appointed to the Board effective January 1, 2016 and was subsequently appointed Chairman of our Audit Committee. Dr. Keegan has more than 30 years of experience in life science businesses. From 2007 to 2012, when it was sold to Pall Corporation, Dr. Keegan was CEO at ForteBio, Inc., a life science tool company, where he helped to lead a financing round and established product development and sales strategies for that company. From 1998 to 2007, Dr. Keegan was CEO at Molecular Devices Corporation (NASDAQ: MDCC), a provider of bioanalytical measurement systems, software and consumables, where Dr. Keegan helped to grow the company, both internally and through acquisitions. From 1992 to 1998, Dr. Keegan worked at Becton Dickinson and Company, a medical technology company that manufactures and sells medical devices and instrument systems, where he served as President of Worldwide Tissue Culture and Vice President, General Manager of Worldwide Flow Cytometry. From 1988 to 1992, Dr. Keegan was Vice President of the Microscopy and Scientific I nstruments Division of Leica, Inc., a life science tool and semiconductor equipment provider. He currently serves on the Board of Directors of Arrayjet LTD, Bio-Techne (NASDAQ:TECH), Carterra, Halo Labs, Labcyte as Chairman and Nanomedical Diagnostics as Executive Chairman. Dr. Keegan holds a B.A. in Chemistry from Boston University and a Ph.D. in Physical Chemistry from Stanford University.

Eric Lev

Eric Lev was appointed to the Board effective July 15, 2019. Mr. Lev is currently the Series A Director. Mr. Lev has more than 17 years of experience in life science investing. Since 2013, Mr. Lev has been a partner at Ampersand Capital Partners, a middle market private equity firm dedicated to growth-oriented investments in the healthcare sector and an entity affiliated with Ampersand. From 2005 to 2013, Mr. Lev was a principal at Water Street Healthcare Partners, and served before then as Group Manager, Strategy & Business Development at Beckman Coulter from 2004 to 2005. Mr. Lev also previously served as an associate on the healthcare/life sciences team at One Equity Partners and began his career as an analyst in the investment banking division of Lehman Brothers. He currently serves on the boards of directors of private companies within the pharmaceutical services market such as NEOMED-LABS and LakePharma. He previously served on the boards of directors of private companies within the clinical laboratory services market such as Genoptix, PLUS Diagnostics, and ConVerge Diagnostics. Mr. Lev holds a B.A. from Northwestern University and a M.B.A from the University of Chicago. Mr. Lev brings to the Board expertise in finance and extensive knowledge of the life science industry.

Ron Rocca

Ron has significant experience as a senior executive at companies which develop and market high value, proprietary tests. In addition to serving as CEO of Exagen since 2011, Mr. Rocca served as VP of Sales & Marketing and General Manager of Prometheus Laboratories from 2005 to 2011.